TOV-112DHomo sapiens (Human)Cancer cell line
Also known as: TOV112, TOV-112, TOV112D, TOV-112d
Quick Overview
Human ovarian cancer cell line with potential for AKT pathway research.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_3612 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Ovary[UBERON:UBERON_0000992] |
Donor Information
| Age | 42 |
|---|---|
| Age Category | Adult |
| Sex | Female |
| Race | caucasian |
Disease Information
| Disease | Endometrioid carcinoma of ovary |
|---|---|
| Lineage | Ovary/Fallopian Tube |
| Subtype | Endometrioid Ovarian Cancer |
| OncoTree Code | EOV |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000048_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Arg175His (c.524G>A) | Unspecified | Somatic mutation acquired during proliferation | from parent cell line YCC-3 |
| MutationSimple | SMARCA4 | p.Leu639fs (c.1915delC) | Homozygous | - | from parent cell line TOV-112D |
| MutationSimple | CTNNB1 | p.Ser37Ala (c.109T>G) | Homozygous | - | from parent cell line TOV-112D |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines.
Trent J.M., Weissman B.E., Huntsman D.G., Wang Y.-M.
Gynecol. Oncol. 160:568-578(2021).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines.
Velculescu V.E., Scharpf R.B.
Cell Rep. 25:2617-2633(2018).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.
Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.
Nat. Commun. 7:12645.1-12645.14(2016).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.
Noonan A.M., Annunziata C.M.
Gynecol. Oncol. 142:332-340(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.
Helleman J.
PLoS ONE 9:E103988-E103988(2014).
Type-specific cell line models for type-specific ovarian cancer research.
Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.
PLoS ONE 8:E72162-E72162(2013).
Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer.
Arcand S.L., Tonin P.N., Provencher D.M., Mes-Masson A.-M.
BMC Cancer 12:379.1-379.16(2012).
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.
Lessey B.A., Jordan V.C., Bradford A.P.
Gynecol. Oncol. 127:241-248(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Genomic complexity and AKT dependence in serous ovarian cancer.";
Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.
Cancer Discov. 2:56-67(2012).
Radiosensitivity profiles from a panel of ovarian cancer cell lines exhibiting genetic alterations in p53 and disparate DNA-dependent protein kinase activities.
Long S.B.T., Vonguyen L., Chen D.J., Gray J.W., Chen F.-Q.
Oncol. Rep. 23:1021-1026(2010).
Comparative proteomic study of two closely related ovarian endometrioid adenocarcinoma cell lines using cIEF fractionation and pathway analysis.
Dai L., Li C., Shedden K.A., Misek D.E., Lubman D.M.
Electrophoresis 30:1119-1131(2009).
Chromosomes 6 and 18 induce neoplastic suppression in epithelial ovarian cancer cells.
Jacobs I.J., Jones C., Gayther S.A.
Int. J. Cancer 124:1037-1044(2009).
Characterization of three new serous epithelial ovarian cancer cell lines.
Provencher D.M., Mes-Masson A.-M.
BMC Cancer 8:152.1-152.18(2008).
Selenium binding protein 1 in ovarian cancer.";
Bandera C.A., Welch W.R., Berkowitz R.S., Mok S.C., Ng S.-W.
Int. J. Cancer 118:2433-2440(2006).
Microarray analysis of gene expression mirrors the biology of an ovarian cancer model.
Manderson E.N., Provencher D.M., Mes-Masson A.-M.
Oncogene 20:6617-6626(2001).